Maintenance treatment for extensive small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of drugs as a maintenance therapy after initial chemotherapy for extensive-stage small cell lung cancer. It aims to see if this combination can help keep the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with extensive-stage small cell lung cancer.
- You are 18 years or older.
- You have not had any previous treatment for this cancer.
- You are in generally good health (able to care for yourself, up and about).
- You have at least one tumor that can be measured on a CT scan.
- You agree to use effective birth control during and for a period after the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two targeted therapies (adebelimumab, an immunotherapy, and apatinib, a drug that blocks blood vessel growth) after initial chemotherapy can help keep extensive stage small cell lung cancer under control. It is for people who have not yet had systemic treatment for their cancer and are in good enough health to try this maintenance approach.
This study tests a combination of two chemotherapy drugs (irinotecan liposome and a platinum drug) plus an immunotherapy drug and a targeted therapy (anlotinib) as maintenance treatment after initial chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this combination keeps the cancer from growing for as long as possible.
This trial tests a combination of two experimental immunotherapy drugs (ivonescimab and cadonilimab) with standard chemotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination works better than chemo alone.
This trial is testing whether a maintenance therapy using anlotinib (a drug that blocks blood vessel growth) combined with immunotherapy can help keep extensive-stage small cell lung cancer from progressing after initial chemoimmunotherapy. It aims to see if this reduces the chance of the cancer coming back and improves survival.
This study tests whether a combination of two targeted drugs can help keep extensive-stage small cell lung cancer from growing after initial treatment. The goal is to see if this maintenance approach extends the time before the cancer worsens.
This trial tests a combination of two drugs (adebrelimab and etoposide capsules) as maintenance therapy for people with extensive-stage small cell lung cancer who have not progressed after initial treatment. It may help extend the time before the cancer grows back.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.